| 000 | 01709 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250517131448.0 | ||
| 264 | 0 | _c20180201 | |
| 008 | 201802s 0 0 eng d | ||
| 022 | _a1538-7836 | ||
| 024 | 7 |
_a10.1111/jth.13601 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aZhang, Y | |
| 245 | 0 | 0 |
_aAge-stratified outcome of a genotype-guided dosing algorithm for acenocoumarol and phenprocoumon. _h[electronic resource] |
| 260 |
_bJournal of thrombosis and haemostasis : JTH _c03 2017 |
||
| 300 |
_a454-464 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAcenocoumarol _xadministration & dosage |
| 650 | 0 | 4 | _aAge Factors |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 | _aAlgorithms |
| 650 | 0 | 4 |
_aAnticoagulants _xadministration & dosage |
| 650 | 0 | 4 | _aComorbidity |
| 650 | 0 | 4 |
_aCytochrome P-450 CYP2C9 _xgenetics |
| 650 | 0 | 4 | _aEurope |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGenotype |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInternational Normalized Ratio |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPharmacogenetics |
| 650 | 0 | 4 |
_aPhenprocoumon _xadministration & dosage |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aVitamin K Epoxide Reductases _xgenetics |
| 700 | 1 | _ade Boer, A | |
| 700 | 1 | _aVerhoef, T I | |
| 700 | 1 | _avan der Meer, F J M | |
| 700 | 1 | _aLe Cessie, S | |
| 700 | 1 | _aManolopoulos, V G | |
| 700 | 1 | _aMaitland-van der Zee, A H | |
| 773 | 0 |
_tJournal of thrombosis and haemostasis : JTH _gvol. 15 _gno. 3 _gp. 454-464 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/jth.13601 _zAvailable from publisher's website |
| 999 |
_c26711964 _d26711964 |
||